Investment objective of the scheme is to provide long term capital appreciation by investing in equity & equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes objectives will be achieved.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 2.32% | 16.89% | 18.23% | 11.54% | N/A | 18.16% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 4.69% | 59.79% | 95.48% | 72.73% | N/A | 237% |
| Rank within category | 14/19 | 15/18 | 13/18 | 11/18 | 11/17 | 7/14 | 8/12 | 6/10 | 8/9 | N/A | N/A |
| Sector Funds | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Yearly returns | N/A | 53.84% | 19.54% | -12.68% | 37.67% | 35.79% | -4.3% | 9.84% |
| Q1 returns | N/A | -6.46% | -1.89% | -7.23% | -4.61% | 12.03% | -8.33% | -1.6% |
| Q2 returns | N/A | 25.13% | 16.32% | -10.76% | 16.38% | 2.34% | 4.76% | 15.44% |
| Q3 returns | N/A | 21.84% | 4.91% | 6.09% | 12.08% | 19.54% | -1.49% | 2.21% |
| Q4 returns | 5.95% | 7.88% | -0.15% | -0.58% | 10.64% | -0.93% | 1.15% | -5.39% |
1% on or before 30D, Nil after 30D
| Alpha | 1.03769 |
| Beta | 0.5603 |
| Sharpe Ratio | 0.270819 |
| Sortino Ratio | 0.591272 |
| R-Squared | 0.2553 |
| Tracking Error | 3.7826 |
| Downside Risk | 16.4026 |
| Std. Deviation (Annualised) | 13.7994 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth Current | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | -7.42% | -6.38% | 5.15% | 4.71% | -0.23% | 15.22% | 11.84% | 12.5% | 11% | 1,511.49 | 2.37 | 0.23 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.28% |
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.61% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 6.44% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.38% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.52% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.49% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.35% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.62% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 3.51% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.26% |
| Emcure Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.21% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.94% |
| TREPS | Cash & Cash Equivalents and Net Assets | 2.92% | |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.71% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.70% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 2.42% |
| CORONA Remedies Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.27% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.24% |
| Procter & Gamble Health Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.82% |
| Thyrocare Technologies Ltd. | Healthcare Services | Domestic Equities | 1.76% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.68% |
| Jupiter Life Line Hospitals Ltd. | Healthcare Services | Domestic Equities | 1.55% |
| Metropolis Healthcare Ltd. | Healthcare Services | Domestic Equities | 1.48% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.45% |
| Shilpa Medicare Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.43% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.22% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.13% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.13% |
| Sanofi Consumer Healthcare India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.11% |
| Suraksha Diagnostic Ltd. | Healthcare Services | Domestic Equities | 1.10% |
| Manipal Health Enterprises Ltd. | Healthcare Services | Domestic Equities | 1.07% |
| Vijaya Diagnostic Centre Ltd. | Healthcare Services | Domestic Equities | 1.04% |
| Pfizer Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.01% |
| Natco Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.92% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.83% |
| Medi Assist Healthcare Services Ltd. | Insurance | Domestic Equities | 0.73% |
| Vinati Organics Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.69% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 0.64% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 0.60% |
| Jubilant Pharmova Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.60% |
| Net Receivable / Payable | Cash & Cash Equivalents and Net Assets | -0.85% | |
| Total | 100.00% | ||
He has over 11years of work experience in Equity Capital Markets. He has also worked with Morgan Stanley Investment Management, Reliance Capital Asset Management Ltd. and Edelweiss Securities.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
